TY - JOUR
T1 - Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer
T2 - findings from CALGB/SWOG 80702 (Alliance)
AU - Lee, Seohyuk
AU - Ma, Chao
AU - Shi, Qian
AU - Meyers, Jeffrey
AU - Kumar, Pankaj
AU - Couture, Felix
AU - Kuebler, Philip
AU - Krishnamurthi, Smitha
AU - Lewis, De Quincy
AU - Tan, Benjamin
AU - O’Reilly, Eileen M.
AU - Shields, Anthony F.
AU - Meyerhardt, Jeffrey A.
N1 - Funding Information:
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology.) https://acknowledgments.alliancefound.org . UG1CA233163, UG1CA233180, UG1CA233253, UG1CA233290, UG1CA233320, UG1CA233337, UG1CA233339, UG1CA189954, and U10CA180863 to the Canadian Cancer Trials Group; UG1CA233234; and U10CA180820 to the ECOG–ACRIN Cancer Research Group; U10CA180868 to NRG Oncology; and U10CA180888 to the SWOG Cancer Research Network from the National Cancer Institute of the National Institutes of Health. Dr. Meyerhardt is supported by the Douglas Gray Woodruff Chair Fund, the Guo Shu Shi Fund, Anonymous Family Fund for Innovations in Colorectal Cancer, and the George Stone Family Foundation. The National Cancer Institute was involved in the design of the study and review of the manuscript. Pfizer participated in initial protocol development and review and approval of the final manuscript. Pfizer provided celecoxib and placebo tablets. Pfizer was not involved in the collection, management, analysis, or interpretation of the data. Neither Pfizer nor the National Cancer Institute had the right to veto publication or control the decision to which journal the article was submitted. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2023/8/10
Y1 - 2023/8/10
N2 - Background: We sought to assess the influences of sleep duration, sleep adequacy, and daytime sleepiness on survival outcomes among Stage III colon cancer patients. Methods: We conducted a prospective observational study of 1175 Stage III colon cancer patients enrolled in the CALGB/SWOG 80702 randomised adjuvant chemotherapy trial who completed a self-reported questionnaire on dietary and lifestyle habits 14–16 months post-randomisation. The primary endpoint was disease-free survival (DFS), and secondary was overall survival (OS). Multivariate analyses were adjusted for baseline sociodemographic, clinical, dietary and lifestyle factors. Results: Patients sleeping ≥9 h—relative to 7 h—experienced a worse hazard ratio (HR) of 1.62 (95% confidence interval (CI), 1.01–2.58) for DFS. In addition, those sleeping the least (≤5 h) or the most (≥ 9 h) experienced worse HRs for OS of 2.14 (95% CI, 1.14–4.03) and 2.34 (95% CI, 1.26–4.33), respectively. Self-reported sleep adequacy and daytime sleepiness showed no significant correlations with outcomes. Conclusions: Among resected Stage III colon cancer patients who received uniform treatment and follow-up within a nationwide randomised clinical trial, very long and very short sleep durations were significantly associated with increased mortality. Interventions targeting optimising sleep health among indicated colon cancer patients may be an important method by which more comprehensive care can be delivered. Trial registration: ClinicalTrials.gov Identifier: NCT01150045.
AB - Background: We sought to assess the influences of sleep duration, sleep adequacy, and daytime sleepiness on survival outcomes among Stage III colon cancer patients. Methods: We conducted a prospective observational study of 1175 Stage III colon cancer patients enrolled in the CALGB/SWOG 80702 randomised adjuvant chemotherapy trial who completed a self-reported questionnaire on dietary and lifestyle habits 14–16 months post-randomisation. The primary endpoint was disease-free survival (DFS), and secondary was overall survival (OS). Multivariate analyses were adjusted for baseline sociodemographic, clinical, dietary and lifestyle factors. Results: Patients sleeping ≥9 h—relative to 7 h—experienced a worse hazard ratio (HR) of 1.62 (95% confidence interval (CI), 1.01–2.58) for DFS. In addition, those sleeping the least (≤5 h) or the most (≥ 9 h) experienced worse HRs for OS of 2.14 (95% CI, 1.14–4.03) and 2.34 (95% CI, 1.26–4.33), respectively. Self-reported sleep adequacy and daytime sleepiness showed no significant correlations with outcomes. Conclusions: Among resected Stage III colon cancer patients who received uniform treatment and follow-up within a nationwide randomised clinical trial, very long and very short sleep durations were significantly associated with increased mortality. Interventions targeting optimising sleep health among indicated colon cancer patients may be an important method by which more comprehensive care can be delivered. Trial registration: ClinicalTrials.gov Identifier: NCT01150045.
UR - http://www.scopus.com/inward/record.url?scp=85159266523&partnerID=8YFLogxK
U2 - 10.1038/s41416-023-02290-2
DO - 10.1038/s41416-023-02290-2
M3 - Article
C2 - 37179438
AN - SCOPUS:85159266523
SN - 0007-0920
VL - 129
SP - 283
EP - 290
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 2
ER -